Agenus to Present at the Raymond James Virtual Human Health Innovation Conference

Rhea-AI Summary

Agenus Inc. (NASDAQ: AGEN) will have Dr. Jennifer Buell present an update on the company’s progress during the Raymond James Virtual Human Health Innovation Conference on June 18, 2020, from 4:20 PM to 4:50 PM ET. The event will include one-on-one investor meetings. Agenus is focused on immuno-oncology, developing immune checkpoint antibodies, adoptive cell therapies, and cancer vaccines to enhance patient outcomes. For further details, the presentation can be accessed via a webcast at this link.

News Market Reaction – AGEN

+0.84%

+0.84% Session move

In the trading session that priced this news, AGEN gained 0.84%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass., June 17, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, announced today that Dr. Jennifer Buell, PhD, President and Chief Operating Officer of Agenus, will present an update on Agenus' progress and host one-on-one meetings with investors at the Raymond James Virtual Human Health Innovation Conference on June 18, 2020.

Date: Thursday, June 18, 2020

Time: 4:20 pm – 4:450 p.m. ET / Virtual Track 1

Webcast: The presentation will be webcast and can be accessed through the following link: https://kvgo.com/raymondjames/Agenus-june-2020

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.

Contact:
Agenus Inc. 
Jennifer Buell, PhD
781-674-4420 
Jennifer.Buell@agenusbio.com 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/agenus-to-present-at-the-raymond-james-virtual-human-health-innovation-conference-301078831.html

SOURCE Agenus Inc.

FAQ

What is Agenus presenting at the Raymond James Virtual Human Health Innovation Conference?

Agenus will present an update on its progress in immuno-oncology, including developments in immune checkpoint antibodies and cancer therapies.

When is the Agenus presentation at the Raymond James Conference?

The presentation is scheduled for June 18, 2020, from 4:20 PM to 4:50 PM ET.

How can I watch the Agenus presentation at the conference?

You can access the presentation via webcast at this link.

Who is Dr. Jennifer Buell in relation to Agenus?

Dr. Jennifer Buell is the President and Chief Operating Officer of Agenus.

What is the focus of Agenus as a company?

Agenus is focused on discovering and developing therapies that harness the immune system to combat cancer and infections.